Financials Caregen Co., Ltd.

Equities

A214370

KR7214370009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-02 pm EDT			5-day change	1st Jan Change
22,250 ^KRW	+3.97%		+2.06%	-19.09%

2023	Caregen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	Caregen's Net Income Jumps 88.2% in Q1	MT

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	1,347,135	1,351,191	1,174,308	-	-
Enterprise Value (EV) ²	1,347	1,320	1,163	1,139	1,102
P/E ratio	49.4 x	33.8 x	26.4 x	20.2 x	-
Yield	-	2.33%	2.68%	2.68%	2.68%
Capitalization / Revenue	-	17.1 x	12.6 x	10.1 x	8.7 x
EV / Revenue	-	16.7 x	12.5 x	9.82 x	8.17 x
EV / EBITDA	-	29.1 x	21.5 x	16 x	12.8 x
EV / FCF	-	64.5 x	11.1 x	20.7 x	16 x
FCF Yield	-	1.55%	9.03%	4.83%	6.26%
Price to Book	-	5.94 x	4.88 x	4.4 x	3.84 x
Nbr of stocks (in thousands)	49,130	49,134	49,134	-	-
Reference price ³	27,420	27,500	23,900	23,900	23,900
Announcement Date	3/14/23	2/5/24	-	-	-

¹KRW in Million²KRW in Billions³KRW

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	-	79.21	93	116	135
EBITDA ¹	-	45.36	54	71	86
EBIT ¹	-	40.38	49	66	81
Operating Margin	-	50.98%	52.69%	56.9%	60%
Earnings before Tax (EBT) ¹	-	49.57	56	74	90
Net income ¹	27.27	39.93	45	58	70
Net margin	-	50.41%	48.39%	50%	51.85%
EPS ²	555.6	813.0	907.0	1,182	-
Free Cash Flow ³	-	20,447	105,000	55,000	69,000
FCF margin	-	25,813.79%	112,903.23%	47,413.79%	51,111.11%
FCF Conversion (EBITDA)	-	45,077.56%	194,444.44%	77,464.79%	80,232.56%
FCF Conversion (Net income)	-	51,207.38%	233,333.33%	94,827.59%	98,571.43%
Dividend per Share ²	-	640.0	640.0	640.0	640.0
Announcement Date	3/14/23	2/5/24	-	-	-

¹KRW in Billions²KRW³KRW in Million

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4
Net sales ¹	24.67	18.38	18.72	17.44
EBITDA	-	-	-	-
EBIT ¹	12.52	7.636	9.875	10.34
Operating Margin	50.77%	41.54%	52.76%	59.3%
Earnings before Tax (EBT)	-	-	-	-
Net income ¹	-	7.439	9.8	8.544
Net margin	-	40.47%	52.36%	48.99%
EPS	-	-	-	-
Dividend per Share	-	-	-	-
Announcement Date	5/4/23	8/9/23	11/10/23	2/5/24

¹KRW in Billions

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	-	31.5	11	35	72
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ²	-	20,447	105,000	55,000	69,000
ROE (net income / shareholders' equity)	-	18%	19.1%	22.9%	24.6%
ROA (Net income/ Total Assets)	-	-	-	-	-
Assets ¹	-	-	-	-	-
Book Value Per Share ³	-	4,626	4,893	5,436	6,229
Cash Flow per Share	-	-	-	-	-
Capex ¹	-	8.16	65	-	-
Capex / Sales	-	10.3%	69.89%	-	-
Announcement Date	3/14/23	2/5/24	-	-	-

¹KRW in Billions²KRW in Million³KRW

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Caregen Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

23,900 KRW

Average target price

24,000 KRW

Spread / Average Target

+0.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CAREGEN CO., LTD.	-19.09%	797M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+13.53%	41.95B
OTSUKA HOLDINGS CO., LTD.	+22.20%	22.53B
CIPLA LIMITED	+17.35%	14.11B
ZYDUS LIFESCIENCES LIMITED	+45.62%	12.5B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.44%	6.75B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.55%	5.6B
GEDEON RICHTER	+4.00%	4.95B

Generic Pharmaceuticals